Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2020 | Transfusion-dependant, low-risk MDS: what are the options?

Valeria Santini • 17 Mar 2020
MDS 2020
Myelodysplastic Syndromes Galunisertib Luspatercept Sotatercept

Valeria Santini, MD, University of Florence, Florence, Italy, discusses the therapy options for transfusion-dependent, low-risk myelodysplastic syndromes (MDS) patients. Specifically, the stimulation of erythropoiesis with the TGF-β targetting galunisertib and the ligand-trapping luspatercept and sotatercept is outlined. This interview was recorded during an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Valeria Santini

2:57
Imetelstat for LR-MDS: insights from the IMerge trial
Valeria Santini • 11 Dec 2023
2:52
Long-term evaluation of luspatercept in ESA-intolerant/refractory LR-MDS: MEDALIST follow-up study
Valeria Santini • 11 Dec 2023
1:34
Managing adverse events with novel therapies in lower-risk MDS
Valeria Santini • 7 Sep 2023
2:25
Approaching ESA failure in patients with lower-risk MDS
Valeria Santini • 7 Sep 2023

Related Videos

2:22
Haplo-SCT for older patients with AML/MDS, and should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals